Join the Irish Cancer Society Collaborative Research Centre BREAST-PREDICT for a two-day celebratory symposium to mark the centre’s 5th birthday. The event is envisaged as a multidisciplinary overview of BREAST-PREDICT achievements and current advances in breast cancer research and clinical trials, with talks from national and international speakers.
Researchers, investigators, clinicians and everyone interested welcome to attend upon free registration! Coffee breaks & light lunch provided.
—————————————————————————————————————————————————-
PROGRAMME
Wednesday 17th October 2018, 9:30 – 16:50 UCD Conway Lecture Theatre
9:30 – 10:00 Registration and coffee
10:00 – 10:20 Welcome address and overview of BREAST-PREDICT, Irish Cancer Society’s 1st Collaborative Cancer Research Centre: Prof. William Gallagher, Director of the UCD Conway Institute, Director of BREAST-PREDICT and Chief Scientific Officer at OncoMark Ltd.
10:20 – 11:00 Keynote: Beyond routine cancer registration: the role of clinical cancer registers in support of quality control and research
Prof. Mats Lambe, Department of Medical Epidemiology and Biostatistics (MEB), Karolinska Institutet (Stockholm, Sweden)
11:00 – 11:30 Drug repurposing for breast cancer: focus on aspirin, statins and vitamin D
Prof. Kathleen Bennett, Division of Population Health Sciences, Royal College of Surgeons in Ireland and Health Research Board (HRB) Research Leader
11:30 – 11:50 Coffee break
11:50 – 12:20 Overview of the breast cancer portfolio of Cancer Trials Ireland studies
Dr. Verena Murphy, Translational Research Leader, Cancer Trials Ireland
12:20 – 12:50 Mutant p53 as a New Target for the Treatment of Triple-Negative Breast Cancer?
Prof. Joe Duffy, School of Medicine, University College Dublin and St Vincent’s University Hospital
12:50 – 13:20 BET Inhibition as a therapeutic strategy for Invasive Lobular Breast Cancer
Prof. Darran O’Connor, Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland
13:20 – 14:10 Lunch
14:10 – 14:35 Biomarkers of response to TCHL based neo-adjuvant treatment of HER2-positive breast cancer
Dr. Alex Eustace, Research Lead for Molecular Therapeutics for Cancer in Ireland, The National Institute for Cellular Biotechnology, Dublin City University
14:35 – 15:00 Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets
Dr. Damir Varešlija, Department of Surgery, Royal College of Surgeons in Ireland
15:00 – 15:25 Targeting the PI3K pathway to overcome anti-Her2 therapy resistance in HER2-positive breast cancer
Dr. Sinead Toomey, Lecturer, Royal College of Surgeons in Ireland
15:25 – 15:35: Coffee break
15:35 – 16:50 PhD Showcase Session
Michelle Lowry, Trinity College Dublin: Investigating the role of CAIX in the mechanisms of HER2-targeted drug resistance in breast cancer cells and extracellular vesicles
Dr. Ben Doherty, Royal College of Surgeons in Ireland: ADAM22 as a therapeutic target for endocrine resistant metastatic breast
Amelia Smith, Trinity College Dublin: Pharmacoepidemiological studies in breast and colorectal cancer; the association between statins and cancer outcomes
Luis Martinez, Systems Biology Ireland, University College Dublin: Interference of gene regulatory networks in breast cancer
Dr. Lisa Dwane, Royal College of Surgeons in Ireland: The role of USP11 in endocrine-driven breast cancer
18:00 – 19:15: PUBLIC SEMINAR – Breast cancer – a growing global challenge?
VENUE: Albert Theatre, Royal College of Surgeons in Ireland (123 St Stephen’s Green, Dublin 2, York Street Entrance)
Guest speaker: Prof. Elisabete Weiderpass – Professor of Cancer Epidemiology at University of Tromsø (Norway) & Karolinska Institutet (Sweden), Head of the Research Department at the Cancer Registry of Norway, and Leader of the Genetic Epidemiology group at Folkhälsan Research Centre at the University of Helsinki in Finland. Director of the International Agency for Research on Cancer (IARC), World Health Organization, from 1st January 2019 onwards.
***End of Day 1***
Thursday 18th October 2018, 9:30 – 13:30 UCD Conway Lecture Theatre
9:30 – 10:00 Registration and coffee
10:00 – 10:40 Keynote: Dynamic epigenetic regulation: single cells can make the difference Prof. Pernette Verschure, The Swammerdam Institute for Life Sciences, University of Amsterdam (Amsterdam, The Netherlands)
10:40 – 11:10 Deregulation of transcription in breast cancer
Prof. Adrian Bracken, Smurfit Institute of Genetics, Trinity College Dublin
11:10 – 11:30 Translation of novel targeted therapeutic approaches for breast cancer to clinical trials
Prof. John Crown, Professor and consultant medical oncologist at St. Vincent’s University Hospital, Chief Medical Officer at OncoMark Ltd.
11:30 – 11:50 Targeting PP2A with LB-100 in HER2-positive breast cancer. A novel approach to overcome acquired lapatinib resistance
Dr. Neil Conlon, The National Institute for Cellular Biotechnology, Dublin City University
11:50 – 12:10 Coffee break
12:10 – 12:40 How systems biology can accelerate drug target discovery and development
Prof. Walter Kolch, Director of Systems Biology Ireland, University College Dublin
12:40 – 13:20 Keynote: Multilevel molecular analyses in breast cancer: gauging inter- and intra-tumor heterogeneity and elucidating its role in treatment response
Prof. Anne-Lise Børresen-Dale, Professor Emeritus at The Institute for Cancer Research, University of Oslo (Oslo, Norway)
13:20 – 13:30 Conclusions
Prof. William Gallagher, Director of the UCD Conway Institute, Director of BREAST-PREDICT and Chief Scientific Officer at OncoMark Ltd.
13:30 Lunch
***End of Day 2***
—————————————————————–
For any queries, please contact: luciana.herda@ucd.ie.
Directions to UCD Conway Institute of Biomolecular and Biomedical Research: https://www.ucd.ie/conway/aboutus/contactus/